These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18687492)

  • 1. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use.
    Eroglu E; Gemici G; Bayrak F; Kalkan AK; Degertekin M
    Int J Cardiol; 2009 Oct; 137(2):e43-5. PubMed ID: 18687492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine].
    Pöss J; Böhm M; Link A
    Dtsch Med Wochenschr; 2010 May; 135(19):965-8. PubMed ID: 20446231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine-induced acute myocardial infarction in a young lady.
    Yim KM; Ng HW; Chan CK; Yip G; Lau FL
    Clin Toxicol (Phila); 2008 Nov; 46(9):877-9. PubMed ID: 18788006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial infarction associated with adderall XR and alcohol use in a young man.
    Jiao X; Velez S; Ringstad J; Eyma V; Miller D; Bleiberg M
    J Am Board Fam Med; 2009; 22(2):197-201. PubMed ID: 19264944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute coronary syndrome in a young woman treated with sibutramine.
    Gómez-Barrado JJ; Turégano S; Garcipérez de Vargas FJ; Porras Y
    Rev Esp Cardiol; 2010 Feb; 63(2):243. PubMed ID: 20109425
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial infarction associated with sibutramine use: case report and discussion.
    Fernandez WG; Biswas AK
    Mil Med; 2010 Aug; 175(8):622-4. PubMed ID: 20731270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D; Gershenzon A; Corallo CE; Nagappan R
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
    Jordan J; Scholze J; Matiba B; Wirth A; Hauner H; Sharma AM
    Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute myocardial infarction in cocaine addicts].
    Martínez Sande JL; Martínez-Escauriaza Alonso JM; Amaro Cendón A; Rozas Lozano P; Losada Palmón S; Pérez Rodríguez M; Folla Macía M; Gil de la Peña M
    Rev Esp Cardiol; 1993 Feb; 46(2):111-5. PubMed ID: 8451480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The obese older female patient: CV risk and the SCOUT study.
    Coutinho WF
    Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S26-30; discussion S31-2. PubMed ID: 17968434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S; Hansen DL; Hilsted JC; Porsborg PA; Astrup AV;
    Ugeskr Laeger; 2001 May; 163(21):2935-40. PubMed ID: 11402974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.